Evidence map›Paper›PMID 24829544›Full record

ArticleGastroenterology & hepatology2014

Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation.

Vignan Manne, Ruby M Allen, Sammy Saab

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Gastroenterology & hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Managing HBV and HCV Infection Pre- and Post-liver Transplant.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Vignan ManneDr Manne and Ms Allen are research assistants in the Department of Surgery and Dr Saab is a professor of medicine and surgery in the Departments of Medicine and Surgery at the University of California, Los Angeles in Los Angeles, California.
Ruby M AllenDr Manne and Ms Allen are research assistants in the Department of Surgery and Dr Saab is a professor of medicine and surgery in the Departments of Medicine and Surgery at the University of California, Los Angeles in Los Angeles, California.
Sammy SaabDr Manne and Ms Allen are research assistants in the Department of Surgery and Dr Saab is a professor of medicine and surgery in the Departments of Medicine and Surgery at the University of California, Los Angeles in Los Angeles, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus (HBV) infection is an international public health concern, and chronic infection can lead to the development of cirrhosis, liver failure, or hepatocellular carcinoma as well as the need for liver transplantation. The recurrence of HBV infection following liver transplantation was disproportionately high prior to the introduction of proper prophylactic treatment. Risk factors associated with the recurrence of HBV infection post-transplant include hepatitis B e antigen positivity, high levels of serum HBV DNA, and the presence of an antiviral drug-resistant strain prior to transplantation. The prevention of HBV recurrence began with the introduction of hepatitis B immunoglobulin (HBIG) in the early 1 990s. Nucleos(t)ide analog (NA) antiviral drugs were next to be introduced and, in combination with HBIG, are considered to be extremely effective for the prevention of recurrence. Because of concerns with HBIG, whether HBIG can be used for a short time or discontinued altogether is under debate. All of the NA antiviral drugs have been proven to be effective against HBV, at least in the pretransplant setting, and can be used safely posttransplant. Further investigation is still needed to standardize treatment in the posttransplant setting.

Indexed as

Hepatitis B virushepatocellular carcinomaliver transplantationposttransplantationpreventionrisk factors

Identifiers

PMID24829544
PMCPMC4014049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.